Liquid biopsy recently became a very promising diagnostic method that has several
advantages over conventional invasive methods. Liquid biopsy may serve as a source of …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genoty**, such as next-generation …

Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive “liquid biopsy”
tool in precision medicine. ctDNA-genomic DNA fragments that are released into the …

Circulating cell-free DNA (cfDNA) is one of the fastest growing and most exciting areas in
oncology in recent years. Its potential clinical uses cover now each phase of cancer patient …

Melanoma is the most aggressive form of skin cancer, representing approximately 4% of all
cutaneous neoplasms it accounts for up to 80% of deaths. Advanced stages of melanoma …

Abstract Introduction: Circulating tumour DNA (ctDNA) is an emerging biomarker in
melanoma. We performed a systematic review and meta-analysis to explore its clinical utility …

The treatment and management of patients with metastatic melanoma have evolved
considerably in the “era” of personalized medicine. Melanoma was one of the first solid …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …